Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma

[1]  Y. Okada,et al.  Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. , 2012, The American journal of pathology.

[2]  G. Opelz,et al.  Treatment of Kidney Transplant Recipients With ACEi/ARB and Risk of Respiratory Tract Cancer: A Collaborative Transplant Study Report , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  M. Lai,et al.  Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Kikuchi,et al.  Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. , 2011, Urology.

[5]  M. Babjuk,et al.  European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. , 2011, European urology.

[6]  K. Kihara,et al.  Phase‐II trial of combination treatment of interferon‐α, cimetidine, cyclooxygenase‐2 inhibitor and renin‐angiotensin‐system inhibitor (I‐CCA therapy) for advanced renal cell carcinoma , 2011, Cancer science.

[7]  R. Hannan,et al.  The renin–angiotensin system and cancer: old dog, new tricks , 2010, Nature Reviews Cancer.

[8]  N. Sasahira,et al.  Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine , 2010, British Journal of Cancer.

[9]  E. Kikuchi,et al.  Cis-dichlorodiammineplatinum Upregulates Angiotensin II Type 1 Receptors through Reactive Oxygen Species Generation and Enhances VEGF Production in Bladder Cancer , 2010, Molecular Cancer Therapeutics.

[10]  M. Stifelman,et al.  Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. , 2010, European urology.

[11]  J. Coleman,et al.  The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. , 2010, European urology.

[12]  Lukasz Januszkiewicz.  [Commentary to the article: Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomized controlled trials. Lancet Oncology, 2010; DOI:10.1016/S1470-2045(10)70106-6]. , 2010, Kardiologia polska.

[13]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[14]  D. Rowland,et al.  Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. , 2010, The Lancet. Oncology.

[15]  R. Millikan,et al.  Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma , 2010, Cancer.

[16]  B. Lane,et al.  Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy , 2010, Cancer.

[17]  H. Yoshiji,et al.  Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. , 2009, Journal of hepatology.

[18]  V. Margulis,et al.  Adjuvant chemotherapy for high-risk upper tract urothelial carcinoma: Results from the Upper Tract Urothelial Carcinoma Collaboration. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Osieka,et al.  Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy , 2009, Journal of Cancer Research and Clinical Oncology.

[20]  Y. Lotan,et al.  Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.

[21]  K. Pienta,et al.  A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. , 2009, Cancer research.

[22]  R. Sidman,et al.  Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis? , 2008, Cancer research.

[23]  M. Weinstock,et al.  Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. , 2008, Journal of the National Cancer Institute.

[24]  Jaclyn H Neo,et al.  The renin-angiotensin system and malignancy. , 2008, Carcinogenesis.

[25]  E. Kikuchi,et al.  Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer , 2007, The Prostate.

[26]  A. Grandi,et al.  Blockade of the renin-angiotensin-aldosterone system: effects on hypertensive target organ damage. , 2006, Cardiovascular & hematological agents in medicinal chemistry.

[27]  M. Nørgaard,et al.  A Cohort Study of Antihypertensive Medication Use and Breast Cancer Among Danish Women , 2006, Breast Cancer Research and Treatment.

[28]  E. Kikuchi,et al.  Angiotensin II Type 1 Receptor Antagonist Candesartan as an Angiogenic Inhibitor in a Xenograft Model of Bladder Cancer , 2006, Clinical Cancer Research.

[29]  Y. Kubota,et al.  Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer , 2005, International Journal of Clinical Oncology.

[30]  S. Johansson,et al.  Urothelial carcinoma of the upper urinary tract: comparison between the WHO/ISUP 1998 consensus classification and WHO 1999 classification system. , 2005, Urology.

[31]  F. Ito,et al.  Primary site and incidence of lymph node metastases in urothelial carcinoma of upper urinary tract. , 2005, Urology.

[32]  J. Sotelo,et al.  Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma , 2005, British Journal of Cancer.

[33]  I. Bairati,et al.  Antihypertensive Drug Use and The Risk of Prostate Cancer (Canada) , 2004, Cancer Causes & Control.

[34]  R. Janzer,et al.  Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma , 2004, British Journal of Cancer.

[35]  N. Weiss,et al.  Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years , 2003, Cancer.

[36]  A. Muscella,et al.  Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells , 2003, Journal of cellular physiology.

[37]  T. Matsuishi,et al.  Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. , 2003, The Journal of clinical investigation.

[38]  A. Miyajima,et al.  Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. , 2002, Cancer research.

[39]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[41]  T. Carmody,et al.  Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. , 1998, Urology.

[42]  H. Miyake,et al.  The significance of lymphadenectomy in transitional cell carcinoma of the upper urinary tract. , 1998, British journal of urology.

[43]  L. Murray,et al.  Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? , 1998, The Lancet.

[44]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[45]  M. Wallander,et al.  Association between captopril, other antihypertensive drugs and risk of prostate cancer , 2004, The Prostate.

[46]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.